tiprankstipranks
Intellia ATTR, HAE studies progressing as planned, says JPMorgan
PremiumThe FlyIntellia ATTR, HAE studies progressing as planned, says JPMorgan
1M ago
Intellia Therapeutics price target lowered to $40 from $60 at Oppenheimer
Premium
The Fly
Intellia Therapeutics price target lowered to $40 from $60 at Oppenheimer
1M ago
Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital
Premium
The Fly
Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital
1M ago
Intellia Therapeutics announces retirement of CSO Laura Sepp-Lorenzino
PremiumThe FlyIntellia Therapeutics announces retirement of CSO Laura Sepp-Lorenzino
1M ago
Intellia Therapeutics: Phase 3 HAELO study to complete enrollment in 2H25
Premium
The Fly
Intellia Therapeutics: Phase 3 HAELO study to complete enrollment in 2H25
1M ago
Intellia Therapeutics price target lowered to $47 from $54 at RBC Capital
Premium
The Fly
Intellia Therapeutics price target lowered to $47 from $54 at RBC Capital
2M ago
Intellia announces FDA granted RMAT designation to nexiguran ziclumeran
PremiumThe FlyIntellia announces FDA granted RMAT designation to nexiguran ziclumeran
3M ago
Cathie Wood’s ARK Investment buys 223.5K shares of Intellia Therapeutics today
Premium
The Fly
Cathie Wood’s ARK Investment buys 223.5K shares of Intellia Therapeutics today
3M ago
Intellia Therapeutics Announces Promising CRISPR Therapy Results
Premium
Company Announcements
Intellia Therapeutics Announces Promising CRISPR Therapy Results
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100